Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppr
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: A clinical and radiological study
β Scribed by Linda Y. Chak; Leslie M. Zatz; Philip Wasserstein; Richard S. Cox; Paula D. Kushlan; Klaus J. Porzig; Branimir I. Sikic
- Publisher
- Elsevier Science
- Year
- 1986
- Tongue
- English
- Weight
- 673 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0360-3016
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Neurologic complications of small cell lung cancer (sC1.C) are manifold. The incidence and course of the various metastatic and nonmetastatic neurologic disorders were studied prospectively in a cohort of SCLC patients. ## METHODS. The 203 patients underwent neurologic examinations
## Abstract ## Purpose The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent nonβsmallβcell lung cancer (NSCLC). ## Methods and Materials From June 1989 t
Thirty-three patients with small cell carcinoma of the lung were treated surgically, and immunohistochemistry of the cell differentiations was examined in detail. The overall 5-year survival rate was 38% and the rates in patients with stage I or stage III were 57% and 11%, respectively (P less than